Slides: PCSK9 inhibition across a wide spectrum of patients: One size fits all?
The slides are prepared and presented by the speaker during a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona. The slides are an educational service to registered PACE members only. PACE is not responsible for the content, opinions expressed in the slides
Kees Hovingh, MD is an internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK. Hovingh is co-chair of the department of internal medicine at the AMC and in his role as head of the clinical trial unit involved in a large number of clinical trials, mainly focused on novel therapies to combat (the consequences of) dyslipidemia.
This symposum was supported by unrestricted educational grants provided by Amgen and Sanofi-Regeneron.
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-CME.